In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad Seeking Distributor For SoundScan Bone Sonometer Approved By FDA

This article was originally published in The Gray Sheet

Executive Summary

Myriad Ultrasound currently is negotiating with a number of potential U.S. distributors for its SoundScan family of bone sonometers following FDA approval, announced June 3.

You may also be interested in...



Sunlight To Pursue Omnisense Bone Sonometer Multi-Site Indications In U.S.

Sunlight Ultrasound Technologies plans to pursue FDA approval of multi-site indications for its Omnisense ultrasound bone sonometer following Jan. 20 premarket approval for assessing skeletal fragility along the distal radius (wrist) bone.

COVID-19: WHO Supports Pooling Of Rights, MPP Includes Drugs and Tests

Intellectual property rights are in the spotlight again, after the World Health Organization and the Medicines Patent Pool announced initiatives to help ensure that all countries will be able to access products being developed for COVID-19.

UsernamePublicRestriction

Register

MT010171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel